Background and Purpose: Comparative effectiveness and safety of oral anticoagulants in
patients with atrial fibrillation and high polypharmacy are unknown. Methods: We used …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

Importance The comparative effectiveness of rivaroxaban and apixaban, the most frequently
prescribed oral anticoagulants for ischemic stroke prevention in patients with atrial …

Background—Patients with atrial fibrillation (AF) often take multiple medications. Methods
and Results—We examined characteristics and compared adjusted outcomes between …

Background and Purpose—Oral anticoagulation therapy is standard of care for patients with
nonvalvular atrial fibrillation to prevent stroke. This study compared rivaroxaban and …

Importance Comparative effectiveness and safety of oral anticoagulants in patients with
atrial fibrillation (AF) and multiple chronic conditions (MCC) are unknown. Objective To …

Objectives In a previous real-world study, rivaroxaban reduced the risk of stroke overall and
severe stroke compared with warfarin in patients with nonvalvular atrial fibrillation (NVAF) …

Background and Purpose—Limited real-world data exist comparing each non–vitamin K
antagonist oral anticoagulant (NOAC) to warfarin in patients with nonvalvular atrial …

Background Novel oral anticoagulants are the cornerstone of therapy for non‐valvular atrial
fibrillation patients to lower the risk of ischaemic stroke. Given the lack of head‐to‐head …

Background The introduction of non–vitamin K antagonist oral anticoagulants has been a
major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in …